1Sandercock P. Immediate anticoagulation for acute stroke in atrial fibrillation. Stroke, 2006,37 : 3054-3055.
2Kwok L, Molckovsky D, Boucher M. Ximelagatran: a new type of oral anticoagulant. Int J Technol Assess Health Care, 2005,21 : 480-486.
3Gurewich V. Ximelagatran--promises and concerns. JAMA, 2005,293:736- 739.
4Coppell JA, Thalheimer U, Zambruni A, et al. The effects of unfractionated heparin, low molecular weight heparin and danaparoid on the thromboelastogram (TEG) : an in-vitro comparison of standard and heparinase-modified TEGs with conventional coagulation assays. Blood Coagul Fibrinolysis, 2006,17:97- 104.
5Kominiarek MA, Angelopoulos SM, Shapiro NL, et al. Lowmolecular-weight heparin in pregnancy: peripartum bleeding complications. Perinatol, 2007,27 :329-334.
6Ibbotson T, Perry CM. Danaparoid: a review of its use in thromboembolic and coagulation disorders. Drugs, 2002,62: 2283-2314.
7Camerlingo M, Salvi P, Belloni G, et al. Intravenous heparin started within the first 3 hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions. Stroke, 2005,36 : 2415-2420.
8Paciaroni M, Agnelli G, Micheli S, et al. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke--a meta-analysis of randomized controlled trials. Stroke, 2007,38 :423-430.
9Kasner SE, Lynn MJ, Chimowitz MI, et al. Warfarin vs aspirin for symptomatic intracranial stenosis:subgroup analyses from WASID. Neurology, 2006,67 : 1275-1278.
10Wong KS, Chen C, Ng PW, et al. Low-molecular-weight heparm compared with aspirin for the treatment of acute ischaemie stroke in Asian patients with large artery occlusive disease: a randomized study. Lancet Neurol, 2007,6:407-413.
9Wardaw JM. Overview of Cochrane thrombolysis meta-analysis [J]. Neurology, 2001, 57(5 SuppI 2): S69-76.
10Merlini PA, Bauer KA, Otrona L, et al. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction [J]. J Am Coll Cardiol, 1995, 25(1): 203-209.
